Table 2.
Risk factors by severity n (%)
| Mild | Moderate | Severe | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Age (p = 0.046) | |||
| < 30 | 0(0) | 7(87.5) | 1(12.5) |
| 30–45 | 3(13) | 16(69.6) | 4(17.4) |
| 45–60 | 12(19.7) | 36(59) | 13(21.3) |
| 60–75 | 9(10.1) | 45(50.6) | 35(39.3) |
| > 75 | 13(17.1) | 35(46.1) | 28(36.8) |
| Gender (p = 0.049) | |||
| Male | 21(14.2) | 73(49.3) | 54(36.5) |
| Female | 16(14.7) | 66(60.6) | 27(24.8) |
| Hypertension | |||
| No | 15(12) | 74(59.2) | 36(28.8) |
| Yes | 19(15.7) | 59(48.8) | 43(35.5) |
| ACEIa intake | |||
| No | 6(8) | 42(56.8) | 26(35.1) |
| Yes | 7(20) | 15(42.9) | 13(37.1) |
| ARBb intake | |||
| No | 8(11) | 37(50.7) | 28(38.4) |
| Yes | 4(11.1) | 19(52.8) | 13(36.1) |
| Dyslipidaemia | |||
| No | 19(13.3) | 84(58.7) | 40(28) |
| Yes | 13(12.7) | 49(48) | 40(39.2) |
| Statins intake | |||
| No | 19(12.8) | 88(59.1) | 42(28.2) |
| Yes | 9(11.3) | 39(48.8) | 32(40) |
| Diabetes | |||
| No | 23(12.9) | 102(57.3) | 53(29.8) |
| Yes | 9(13.2) | 33(48.5) | 26(38.2) |
| Obesity | |||
| No | 20(12) | 95(56.9) | 52(31.1) |
| Yes | 3(8.8) | 17(50) | 14(41.2) |
| Primary Immunodeficiency | |||
| No | 27(11.6) | 130(55.8) | 76(32.6) |
| Yes | 0(0) | 2(100) | 0(0) |
| Secondary Immunodeficiency | |||
| No | 23(12.4) | 103(55.7) | 59(31.9) |
| Yes | 3(7.3) | 24(58.5) | 14(34.1) |
| Epidemiological background (p = 0.001) | |||
| Nursing home resident | 2(5.6) | 19(52.8) | 15(41.7) |
| Live-in relative | 10(19.2) | 37(71.2) | 5(9.6) |
| Frontline worker | 0(0) | 11(78.6) | 3(21.4) |
| Community transmission | 6(14.3) | 16(38.1) | 20(47.6) |
Abbreviations: ACEIa Angiotensin-converting enzyme inhibitors, ARBb Angiotensin II receptor blockers